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In the last years, many clinical studies have revealed that some cisplatin-treated cancer
survivors have a significantly increased risk of cardiovascular events, being cisplatin-
induced cardiovascular toxicity an increasing concern. The aim of the present work
was to evaluate the cardiovascular alterations induced by different chronic cisplatin
treatments, and to identify some of the mechanisms involved. Direct blood pressure,
basal cardiac (left ventricle and coronary arteries) and vascular (aortic and mesenteric)
functions were evaluated in chronic (5 weeks) saline- or cisplatin-treated male Wistar
rats. Three different doses of cisplatin were tested (1, 2, and 3 mg/kg/week). Alterations
in cardiac and vascular tissues were also investigated by immunohistochemistry,
Western Blot, and or quantitative RT-PCR analysis. Cisplatin treatment provoked a
significant modification of arterial blood pressure, heart rate, and basal cardiac function
at the maximum dose tested. However, vascular endothelial dysfunction occurred at
lower doses. The expression of collagen fibers and conexin-43 were increased in cardiac
tissue in cisplatin-treated rats with doses of 2 and 3 mg/kg/week. The expression
of endothelial nitric oxide synthase was also modified in cardiac and vascular tissues
after cisplatin treatment. In conclusion, chronic cisplatin treatment provokes cardiac and
vascular toxicity in a dose-dependent manner. Besides, vascular endothelial dysfunction
occurs at lower doses than cardiac and systemic cardiovascular toxicity. Moreover,
some structural changes in cardiac and vascular tissues are also patent even before
any systemic cardiovascular alterations.
Keywords: cisplatin, cardiac toxicity, vascular toxicity, endothelial dysfunction, autonomic neuropathy
INTRODUCTION
Cancer is among the leading causes of death worldwide. However, due to advances in early
recognition and novel treatment modalities, cancer survival is improving. Unfortunately, with
the improvement in morbidity and mortality rates due to cancer, the increase in long-term
cardiac and vascular toxicity associated with cancer treatments has become an important concern.
Cardiovascular side effects negatively impact quality of life and survival of patients. Moreover, the
development of toxicity may require adjustments or discontinuation of the chemotherapy regimen,
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leading to worse outcomes. As such, early recognition of
cardiovascular dysfunctions associated to the different
chemotherapeutic agents becomes imperative (Curigliano
et al., 2012; Hamo and Bloom, 2015; Denegri et al., 2016).
Cis-dichlorodiamine platinum (cisplatin) is an effective and
widely used chemotherapeutic agent against various solid tumors,
including those affecting the bladder, testicles, and ovaries
(Mollman, 1990). Sensory neuropathy and renal damage are two
of the common side effects that limit therapy with cisplatin.
Neural damage provoked by cisplatin involves central, peripheral,
and autonomic nerves (Boogerd et al., 1990). In relation to
renal injury, it has been described that this antitumoral agent
causes tubular damage and tubular dysfunction with sodium,
potassium, and magnesium wasting, provoking, depending on
the dose administered, a reversible or an irreversible decrease in
glomerular filtration (Yao et al., 2007).
Cardiovascular alterations, such as hypertension,
hyperlipidemia, and coronary artery disease or myocardial
infarction are additional less frequent, but equally important,
factors that have been also associated with platinum-based
chemotherapy. These events do not appear to be dose dependent
and they may occur during treatment, shortly after treatment, or
in some cases months or years after completion of chemotherapy
(Pai and Nahata, 2000).
In the past few years, cisplatin-induced vascular toxicity
has become an increasing concern, affecting up to 12% of
patients (Gospodarowicz, 2008; Ishioka et al., 2008; Vaughn
et al., 2008). Given the efficacy of cisplatin, vascular toxicity
represents a significant survivorship issue. Both endothelial
dysfunction of large arteries and vascular neuropathy have been
discussed as etiological factors for cisplatin-induced vascular
alterations (Turlapaty and Altura, 1980; Rosenfeld and Broder,
1984; Samuels et al., 1987; Serrano-Castro et al., 2000; Pretnar-
Oblak et al., 2007).
Animal models exist for cisplatin-induced sensory peripheral
neuropathy (Verdú et al., 1999; Authier et al., 2003; Vera et al.,
2007), or cisplatin induced-nephrotoxicity (Vickers et al., 2004)
and there are experimental data about the cardiac toxicity
produced by acute administration of this antitumoral agent
(Al-Majed et al., 2006; Yüce et al., 2007). However, to our
knowledge, no experimental data has been reported so far about
the cardiovascular alterations that may be developed after chronic
administration of cisplatin.
The aim of the present experimental work was to evaluate the
possible cardiovascular alterations induced by different chronic
cisplatin treatments (at doses at which it causes neuropathy, Vera
et al., 2007). Modifications on blood pressure and heart rate (HR),
basal heart function, such as conduit and resistance vascular
reactivity were investigated. Besides, structural and molecular
mechanisms involved in these alterations were also studied.
MATERIALS AND METHODS
The Ethical Committee at Universidad Rey Juan Carlos (URJC)
approved the study. Experimental procedures were carried out
in accordance with the recommendations of this Committee as
well as with the EU directive for the protection of animals used
for scientific purpose (2010/63/UE) and Spanish regulations (RD
109 53/2013).
Animals
Male Wistar rats [240–300 g, Harlan-Iberica (Barcelona, Spain)]
were placed in cages (4–6 animals) and maintained in
environmentally controlled conditions (temperature of 20◦C;
humidity of 60%) with a 12 h light/12 h dark cycle. Animals
were allowed free access to standard laboratory rat chow (Harlan-
Iberica, Barcelona, Spain) and tap water, which was refreshed
every day.
Treatments
After a week of adaptation to the controlled conditions, the
animals were divided into four treatment groups (10–15 animals
per group), saline (0.9% NaCl) and cisplatin (1, 2, and 3 mg/kg,
cumulative dose of 5, 10, and 15 mg/kg, respectively). Saline
or cisplatin were administered intraperitoneally once a week
for five experimental weeks. The maximum injection volume
administered intraperitoneally in the animals was 0.5 ml.
Before each antineoplastic drug injection, 2 ml of sterile saline
solution was given subcutaneously to prevent renal damage via
hyperhydration (Authier et al., 2003).
The doses of cisplatin were chosen based on those commonly
used in experimental protocols in rats to induce a wide range of
toxic effects caused by this anticancer agent that are also observed
in humans (Authier et al., 2003; Malik et al., 2006; Vera et al.,
2007; Cabezos et al., 2010).
Blood Pressure and Heart Rate
Measurements in Anesthetized Rats
In all the animals of the different experimental groups,
after anesthesia with sodium pentobarbital (50 mg/kg
intraperitoneally), a catheter coupled to a pressure transducer
was inserted into the right carotid artery of the animals for
direct measurements of systolic (SBP) and diastolic arterial blood
pressure (DBP) and HR using a PowerLab/4e system (PanLab
S.L., Barcelona, Spain). Recording of these cardiovascular
parameters lasted for 10 min (Abalo et al., 2011).
After blood pressure measurements, the animals were
euthanized, and the following preparations and experiments were
performed.
Isolated Heart Preparation
The hearts were removed and immersed into ice-cold modified
Krebs-Henseleit buffer with the following composition: 118 mM
NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.5 mM
CaCl2, 25 mM NaHCO3, and 10 mM glucose, and 2 nM pyruvate.
Afterward, they were immediately mounted on a Langendorff
set-up, the aortic stump was cannulated and the heart was
retrogradely perfused with the modified Krebs-Henseleit buffer.
The buffer was kept at 37◦C in water-heated jacketed chambers
and gassed with 95% O2/5% CO2. The perfusion rate was
adjusted to 20 ml/min with a peristaltic pump (Gilson Inc,
USA). Coronary perfusion pressure (CPP) was measured by a
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pressure transducer fixed on a side-port of the Langendorff set-
up. Left ventricular developed pressure (LVDP) was measured
by a fluid-filled balloon inserted into the left ventricle and fixed
to a second pressure transducer. The volume of the balloon was
adjusted once at the beginning of the experiment to obtain an
end diastolic pressure (EDP) of 5–10 mm Hg. Both pressure
transducers were coupled to a PowerLab 4e recording system
(PanLab SA, Barcelona, Spain) to measure CPP, LVDP and EDP.
HR was derived from the left ventricle pressure signals (González
et al., 2011). These experiments were carried out in 10–15 isolated
hearts from each experimental group.
At the end of the cardiac function experiments, a portion of
the left ventricle of each heart was separated, frozen at −80◦C
and stored for Western Blot determinations. Another portion of
the left ventricle was processed for histological analysis.
Aortic Ring Preparations
The aorta was carefully excised and placed in ice-cold Krebs-
Henseleit (K-H) solution with the following composition (mM)
(118 NaCl; 4.75 KCl; 1.2 MgSO4; 1.19 KH2PO4; 2.54 CaCl2; 25
NaHCO3; 11 glucose). All connective and perivascular adipose
tissues were removed, with care taken not to disrupt the
endothelium. Transverse vascular rings 3–4 mm long were
prepared. The rings were fixed vertically between two stainless
steel hooks and suspended in a 5-ml jacketed glass organ
bath containing K-H buffer at 37◦C and continuously bubbled
with 95% O2 and 5% CO2. The upper wire was connected
to an isometric force transducer (Grass FT07) and tension
measurements were recorded on a computer (PowerLab/4e
program). The rings were mounted with a resting tension of
2 g. Tissues were equilibrated for 90 min, during which time the
medium was replaced every 15 min.
The aorta contractile and relaxant functions from animals
of all the experimental groups were tested. To assess
contractile function, phenylephrine (Phe) (10−9 M–10−5
M) concentration-response curves were performed. To evaluate
vascular endothelium-dependent- and independent relaxation,
carbachol (10−9 M–10−4 M) or sodium nitroprusside (SNP)
(10−9 M–10−6 M) concentration-response curves, respectively,
were established in Phe (1 µM) (submaximal) precontracted
preparations (Abboud et al., 2009). Only one concentration-
response curve was carried out in each preparation. The different
experiments of vascular reactivity were performed in four
rings of each aorta obtained from the animals of the different
experimental groups.
Contraction responses of the aorta rings are expressed as mean
absolute values and relaxation responses are expressed as the
percentage relaxation of the tone induced by Phe.
A portion of aorta was separated, frozen at −80◦C and stored
for Western Blot determinations. Another portion of aorta was
processed for histological analysis.
Mesenteric Perfused Bed Preparation
The abdominal cavity was opened and the superior mesenteric
artery was dissected and cannulated with a blunted hypodermic
needle (21 G). The mesenteric bed was perfused with 50 ml of
K-H solution containing 1000 IU of heparin and was separated
from the gut by carefully cutting close to the intestinal wall.
The preparation was then placed on a plate (8 cm × 8 cm)
in a humid chamber and perfused with K-H at a constant
flow rate of 5 ml/min, using a peristaltic pump (Gilson
S.A.). The solution was maintained at 37◦C and continually
oxygenated (95% O2/5% CO2). Mesenteric vascular responses
were detected as changes in perfusion pressure (mm Hg).
This was monitored continuously using a pressure transducer
(Transpac IV, Abbot) and recorded using a PowerLab (Powerlab
400, ADinstruments). The preparation was equilibrated for
30 min before experimentation.
The experiments were carried in intact mesenteric beds.
The evaluation of functionality of the vascular bed was carried
out following different procedures. Mesenteric bed contractile
function (Carvalho Leone and Coelho, 2004) was evaluated
by a concentration response curve of Phe (10–80 nmol).
The vasorelaxant function was evaluated on precontracted
bed with a concentration of Phe sufficient to increase the
basal perfusion pressure by 60–100 mmHg. The endothelium-
dependent vasodilatation was evaluated with a concentration-
response curve of carbachol (3 × 10−10 mol–3 × 10−5 mol)
and endothelium-independent vasodilatation was evaluated to
a concentration-response curve of SNP (10−11 mol–10−6 mol).
Doses of different drugs were injected in bolus with a Hamilton
syringe (volume 50 µl) (Paniagua et al., 2016). These experiments
were carried out in 10–15 isolated mesenteric beds from each
experimental group.
Contraction responses of superior mesenteric artery bed are
expressed as mean absolute values and relaxation responses are
expressed as the percentage relaxation of the tone induced by Phe.
Histological Analysis
At the end of the experimental period, samples of heart left
ventricles and aorta rings were obtained from six animals
per experimental group, fixed in buffered 10% formalin and
embedded in paraffin. Histological damage and fibrosis were
evaluated in sections 5 µm wide stained with hematoxylin-eosin
stain (HE) and Masson’s trichrome stain for collagen fibers,
or prepared for immunohistochemistry. Samples were studied
under a Zeiss Axioskop 2 microscope equipped with the image
analysis software package AxioVision 4.6. The analysis was made
by triplicate in 5–8 random per section and specimen fields
under a 20× or 40× objective. The experimenter was blind to
the treatment received by the rat from which the sample under
analysis was obtained.
For immunohistochemistry, samples were washed with
phosphate buffered saline (PBS) with 0.05% Tween 20
(Calbiochem, Darmstadt, Germany). Thereafter sections were
incubated for 10 min in 3% (vol vol−1) in hydrogen peroxide
to inhibit endogenous peroxidase activity and blocked with 1%
PBS-BSA (bovine serum albumin) or calf serum for 30 min to
minimize non-specific binding of the primary antibody. Pilot
experiments performed to determine the optimal antibody
dilution showed that some samples needed to be pretreated
by boiling in 10 mM citrate buffer for 30 min. Sections were
then incubated overnight at 4◦C with the following antibodies:
monoclonal mouse anti-human connexin-43 (1:800; Santa
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Cruz Biotechnology, Santa Cruz, CA, USA); polyclonal rabbit
anti-human eNOS (1:50; Novus Biologicals). After incubation,
samples were washed with PBS-Tween. The peroxidase-based
kit Masvision (Master Diagnostica, Granada, Spain) was used
as secondary antibody. Samples were counterstained with
hematoxylin and coverslips mounted with Eukitt mounting
media (O. Kindler GmbH & Co., Freiburg, Germany). To
determine the level of non-specific staining, the preparations
were incubated without the primary antibody.
Western Blot Analysis
For protein extraction, cardiac and aorta tissues (6–8 samples
from 6 to 8 animals per group) were homogenized with ice-cold
RIPA buffer containing 1 mM EGTA, 1 mM Na3VO4, 1 mM
Na4P2O7, 10 mM NaF and a protease inhibitor cocktail (Roche,
Spain). The homogenates were centrifuged (9300 × g, 10 min,
4◦C) and the supernatant was extracted. Total protein values
were quantified from all preparations using the Bradford method
(Somoza et al., 2007).
Aorta (50 µg) and left ventricle (40 µg) samples were
separated by electrophoresis on a 4–20% (aorta) or 10% (left
ventricle tissue) Mini-protean
R©
TGXTM Precast Gel (Bio-Rad,
Spain) and transferred onto a PVDF membrane. The membranes
were blocked with 3% fat-free milk at room temperature
for 1 h and then incubated at 4◦C overnight with primary
antibody as follows: eNOS 1:250 (aorta), 1:500 (left ventricle
tissue; BD Transduction Laboratories), connexin-43 (1:10000;
left ventricle tissue; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), plasminogen activator inhibitor-1 (PAI-1) 1:500 (aorta,
left ventricle tissue; Abcam, Cambridge, UK) and GAPDH
1:1000 (aorta, left ventricle tissue); Santa Cruz Biotechnology,
Santa Cruz, CA, USA). These incubations were followed by
incubation for 1 h at room temperature with an alkaline
phosphatase-conjugated goat anti-mouse secondary antibody
(1:10000) and subsequent treatment with ECF reagent (Thermo
Fisher Scientific, USA). Protein bands were detected using
Typhoon 9210 (GE Healthcare Life Sciences, USA) and the band
intensity was assessed with ImageJ software (National Institutes
of Health, USA). GAPDH was used as an internal control.
Quantitative Real-time PCR Analysis
mRNAs were evaluated by quantitative real-time PCR. Total
RNA was extracted from frozen cardiac and aorta tissues in
Trizol reagent according to the manufacturer’s specifications
(Invitrogen Life Technologies). The RNA concentrations
were calculated by measuring the absorbance readings
using Nanodrop Spectrophotometer ND-1000 (Nanodrop
Technologies Inc., Willington, DE, USA). A total of 1 µg
of RNA was reverse transcribed into cDNA using the High
Capacity cDNA Archive Kit (Applied Biosystems) according
to manufacturer’s instructions in a 20 µl reaction. PCR was
performed in duplicate for each sample using 4.5 µl of diluted
cDNA as template, 0.5 µl of 20x specific primers/probe mix
and 2x SSO Advanced Universal Probes Supermix (Bio-Rad) in
a 10 µl reaction. The amplification was carried out in an ABI
7500 Fast System (Life Technologies) by using the following
conditions: 30 s, 95◦C, 40 cycles (10 s 95◦C, 30 s 60◦C) in fast
mode. As specific oligonucleotide primers and Taqman probes to
detect amplification, we used Taqman Gene Expression Assays
(Life Technologies): eNOS (Rn02132634_s1) and connexin-43
(Rn01433957_m1). As normalizing internal control, we amplified
ribosomal 18S RNA. These determinations were carried out in
five samples from five animals per group.
Statistical Analysis
Data represent the mean ± SEM of observations obtained from
10 to 15 animals for in vivo and in vitro studies and 5–8
preparations (from different animals) for histological, Western
Blot and quantitative real-time PCR analysis (n). Statistically
significant differences were determined using by two-way or one-
way analysis of variance followed by Bonferroni/Dunn post hoc
test (Prism 4). P-values ≤ 0.05 were considered significant.
Drugs
Cisplatin, phenylephrine, carbachol, and sodium nitroprusside
were obtained from Sigma (Sigma Chemical Company, Poole,
Dorset, UK).
Phenylephrine, carbachol, and sodium nitroprusside were
dissolved in distilled water. Cisplatin was dissolved in saline (0.9%
NaCl).
RESULTS
Effect of Chronic Cisplatin Treatment on
Blood Pressure and Heart Rate
Figure 1 shows the SBP, DBP, and HR in anesthetized rats after
repeated treatment with saline or cisplatin at the three different
doses evaluated.
Saline-treated rats had normotensive values for SBP
(110.72 ± 8.10 mmHg, n = 15) and DBP (76.26 ± 5.35 mm Hg,
n = 15) and normal HR (332.28 ± 37.82 beats/minute, n = 15).
Cisplatin treatment caused only blood pressure alterations
at the maximum dose administered (15 mg, cumulative
dose), provoking, at this dose, a significant decrease in DBP
(47.53 ± 11.08 mmHg, n = 10 P < 0.05 vs. control saline group)
without modifying SBP (92.14 ± 14.15 mmHg, n = 10 P > 0.05
vs. control saline group) and HR (254.72 ± 20.82 beats/minute,
n= 10 P > 0.05 vs. control saline group) (Figure 1).
Effect of Chronic Cisplatin Treatment on
Heart Function
Figure 2 shows the baseline cardiac values of left ventricle
function (LVDP and EDP) and coronary flow (CPP) in the
different groups of rats treated with saline or cisplatin at the three
doses evaluated.
In saline treated rats, the LDVP was 90.57 ± 11.10 mmHg,
n= 12, the EDP was 8.79± 2.98 mmHg, n= 12 and the CPP was
90.91 ± 5.21 mmHg, n = 12. Cisplatin only caused significant
cardiac alterations at the maximum dose administered (15 mg,
cumulative dose), provoking at this dose, a significant decrease in
contractile and relaxant function (as the increase in EDP showed)
of the left ventricle (LVDP and EDP, respectively) (LVDP:
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FIGURE 1 | (A) Systolic blood pressure (SBP), (B) diastolic blood pressure
(DBP), and (C) heart rate (HR) of anesthetized animals chronically treated with
saline (CONTROL) or cisplatin (CPT) 1 mg/kg, 2 mg/kg or 3 mg/kg. Data
represent the mean ± SEM, n = 10–15 animals per experimental group.
A one-way ANOVA followed by Bonferroni/Dunn post hoc test was used for
statistical analysis (+P < 0.05, CPT 3 mg/kg vs. control).
FIGURE 2 | Basal values of (A) left ventricular developed pressure (LVDP),
(B) end diastolic pressure (EDP), and (C) coronary perfusion pressure (CPP) of
isolated hearts from animals chronically treated with saline (CONTROL) or
cisplatin (CPT) 1 mg/kg, 2 mg/kg or 3 mg/kg. Data represent the
mean ± SEM, n = 10–15 preparations per experimental group. A one-way
ANOVA followed by Bonferroni/Dunn post hoc test was used for statistical
analysis (+P < 0.05, CPT 3 mg/kg vs. control).
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55.45± 6.09 mmHg, n= 10 P< 0.05; EDP: 27.03± 5.51 mmHg,
n = 10 P < 0.05 vs. control saline group) without affecting CPP
in comparison with saline treated rats (CPP: 119.17 ± 12.19 mm
Hg, n= 10 P > 0.05 vs. control saline group).
Effect of Chronic Cisplatin Treatment on
Aortic Vascular Function
Figure 3 shows the contractile function (measured as response
to Phe), the endothelial-dependent relaxation (measured
as response to carbachol) and the endothelial-independent
relaxation (measured as response to SNP) in the isolated aorta (a
conduit vessel) of the rats from the different groups treated with
saline or cisplatin at the three doses evaluated.
In the saline-treated group, Phe provoked a concentration-
dependent increase in aortic vascular tone resulting in an Rmax
value of 1.16 ± 0.05 g (n = 15), carbachol caused an endothelial-
dependent concentration-dependent decrease in aortic vascular
tone resulting in a Rmax value of 80.70 ± 3.30% (n = 15),
and SNP caused an endothelial-independent concentration-
dependent decrease in aortic vascular tone resulting in a Rmax
value of 117.74 ± 2.01% (n = 15). The weekly chronic
administration of cisplatin at the three doses assayed, 1, 2,
and 3 mg/kg for 5 weeks (cumulative dose of 5, 10, and
15 mg, respectively) did not affect the aortic vasoconstrictor
response to Phe (Figure 3A), but provoked a clear and
significant inhibition of the carbachol-mediated vasorelaxant
response at the doses of 2 and 3 mg/kg, but not at the
dose of 1 mg/kg of cisplatin. It is important to mention that
the inhibition of the endothelial dependent vasorelaxation was
similar at the two higher cisplatin doses evaluated (2 and
3 mg/kg) (Figure 3B). However, the endothelial-independent
vasorelaxation was only affected by chronic treatment with
cisplatin at the maximum dose assayed (3 mg/kg), which showed
a significant potentiation of this vasorelaxation in aorta rings
from rats treated with this particular dose of the antitumoral
agent (Figure 3C).
Effect of Chronic Cisplatin Treatment on
Mesenteric Vascular Function
Figure 4 shows the contractile function (measured as response
to Phe), the endothelial-dependent relaxation (measured
as response to carbachol) and the endothelial-independent
relaxation (measured as response to SNP) in the perfused
mesenteric bed (a resistance vascular territory) of the rats from
the different groups treated with saline or cisplatin at the three
doses evaluated.
In the saline-treated group, Phe provoked a concentration-
dependent increase in mesenteric vascular tone resulting in an
Rmax value of 99.13 ± 5.45 mm Hg (n = 10), carbachol caused
an endothelial-dependent concentration-dependent decrease
in mesenteric vascular tone resulting in a Rmax value of
70.70 ± 4.07% (n = 12), and SNP caused an endothelial-
independent concentration-dependent decrease in mesenteric
vascular tone resulting in a Rmax value of 83.47± 3.02% (n= 10).
The results obtained in this representative resistance territory
were different from those obtained in the conduit vessel, the
FIGURE 3 | (A) Concentration-response curve of phenylephrine (10−9
M–10−5 M), (B) concentration-response curve of carbachol (10−9 M–10−4
M), and (C) concentration-response curve of sodium nitroprusside (SNP)
(10−9 M–10−6 M) in isolated rat aorta rings from animals chronically treated
with saline (CONTROL, white circles) or cisplatin (CPT) 1 mg/kg (gray circles),
2 mg/kg (black circles) or 3 mg/kg (white squares). Values are expressed as
mean ± SEM, n = 10–15 preparations per experimental group. A two-way
ANOVA followed by Bonferroni/Dunn post hoc test was used for statistical
analysis (∗∗∗P < 0.001, CPT 2 mg/kg vs. control; ++P < 0.01, +++P < 0.001
CPT 3 mg/kg vs. control).
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aorta. The weekly chronic administration of cisplatin provoked
a significant decrease in the mesenteric vasoconstrictor response
to Phe at the highest dose of cisplatin assayed (3 mg/kg)
(Figure 4A), but did not provoke any modification in the
endothelial-dependent or independent vasorelaxant function
in mesenteric bed at any of the cisplatin doses evaluated
(Figures 4B,C).
Cardiovascular Alterations Induced by
Chronic Cisplatin Treatment: Structural
and Molecular Mechanisms Involved
Cisplatin treatment evoked a clear damage in the structure
of cardiac fibers (Figures 5A,B). Normal cardiac architecture
was altered when increasing the dose of cisplatin, appearing
rippled cardiomyocytes and fibrils de-arrangement. Similarly,
connexin-43 expression was also modified showing a more
intense and more diffused location with the higher dose of
cisplatin, 3 mg/kg (Figures 5C,D). Western blot analysis also
revealed that the expression of connexin-43 in cardiac left
ventricle was significantly increased at the cisplatin doses
of 2 mg/kg (P < 0.05) and 3 mg/kg compared with the
control group (P < 0.001) (Figure 6A). Furthermore, connexin-
43 expression was significantly increased in the cisplatin
3 mg/kg group in comparison with the cisplatin 2 mg/kg
group (P < 0.05). However, no changes in connexin-43 mRNA
levels were detected at the two different doses of cisplatin
evaluated in comparison with control group (Figure 6B).
On the other hand, histological preparations showed that
cardiac eNOS expression was more heterogeneous after cisplatin
treatment (Figures 5E,F). Western blot analysis showed that
this eNOS expression was significantly decreased at the doses
of cisplatin 2 mg/kg and 3 mg/kg compared with the control
group (P < 0.001) (Figure 6C), while eNOS mRNA level was
significantly decrease only at the dose of 3 mg/kg, but not at the
dose of 2 mg/kg compared with the control group (P < 0.01)
(Figure 6D).
An elevated level of PAI-1 is also an important diagnostic
marker of cardiac fibrosis (Ghosh and Vaughan, 2012). For that,
the cardiac expression of PAI-1 was analyzed in this study. There
was not any change in the cardiac expression of PAI-1 in both,
cisplatin 2 and 3 mg/kg treated animals with respect to the control
group (P > 0.05) (Figure 7).
Regarding the aorta, the morphological analysis showed
changes in the fiber arrangement in the tunica media, losing
their uneven appearance (Figures 8A,B). eNOS staining was
strongly located in endothelium with certain positive areas
in tunica media that disappeared in the animals treated with
cisplatin 3 mg/kg (Figures 8C,D). However, the cisplatin
treatments did not provoke any modification either in aorta
expression of eNOS or in the eNOS mRNA levels in comparison
with the control group (P > 0.05) (Figures 9A,B). The
expression on PAI-1 was also analyzed in aorta tissue in the
different experimental groups. Aortic expression of PAI-1 was
slightly, but not significantly, increased at the two different
doses of cisplatin evaluated in relation to the control group
(Figure 9C).
FIGURE 4 | (A) Concentration-response curve of phenylephrine
(10 nmol–80 nmol), (B) concentration-response curve of carbachol
(3 × 10−10 mol–3 × 10−5 mol) and (C) concentration-response curve of
sodium nitroprusside (SNP) (3 × 10−11 mol–3 × 10−6 mol) in perfused
mesenteric bed from animals chronically treated with saline (CONTROL, white
circles) or cisplatin (CPT) at 1 mg/kg (gray circles), 2 mg/kg (black circles) or
3 mg/kg (white squares). Values are expressed as mean ± SEM, n = 10–15
preparations per experimental group. A two-way ANOVA followed by
Bonferroni/Dunn post hoc test was used for statistical analysis (+P < 0.05,
CPT 3 mg/kg vs. control).
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FIGURE 5 | Representative images of histology and immunohistochemistry of the effect of cisplatin treatment on rat hearts. Rats were injected
intraperitoneally for 5 weeks with saline (0.9% NaCl, left column) or cisplatin (3 mg/kg week−1, right column). Histological samples embedded in paraffin and stained
with Masson’s trichrome (A,B). Samples processed for immunohistochemistry with anti connexin-43 antibody (black arrows) (C,D) and with anti eNOS (E,F).
Heterogenicity in fiber staining is clearly seen. Bar: 100 µm.
DISCUSSION
This study shows that the chronic treatment with cisplatin causes
dose-dependent cardiovascular alterations. Vascular toxicity
occurs at lower doses than cardiac or systemic cardiovascular
alterations. The cisplatin induced-vascular toxicity could be
cataloged as “silent” because it occurs even in the absence of
any systemic cardiovascular modifications. At high doses of
cisplatin treatment, vascular toxicity is maintained and cardiac
and blood pressure alterations are present. Cisplatin treatment
also produced alterations in the structure of cardiac and vascular
tissue, suggesting a direct cytotoxicity. Changes in connexin-43
and eNOS expression could be related with cardiac functional
alterations after cisplatin treatments.
In recent years, many clinical studies have noted that some
cisplatin-treated cancer survivors have a significantly increased
risk of cardiovascular events (Ishioka et al., 2008; Vaughn
et al., 2008), cisplatin-induced cardiovascular toxicity being
an increasing concern. Although, there are some experimental
data in cardiac toxicity induced after acute administration of
cisplatin (Al-Majed et al., 2006; Yüce et al., 2007), there are
no experimental studies specifically evaluating cardiovascular
alterations after chronic cisplatin treatment, and studying,
at the same time, mechanisms involved in these particular
alterations.
As a first approximation, the present study evaluated general
cardiovascular parameters (blood pressure and HR) in different
cisplatin chronic treatments (1, 2, and 3 mg/kg). The results show
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FIGURE 6 | (A) Representative immunoblots for connexin-43 protein expression in whole cardiac left ventricle. Diagram bars show the results of densitometric
analysis of connexin-43 in whole cardiac left ventricle. Homogenized samples from heart show essentially the connexin-43 in its phosphorylated form (strongest
bands for the quantification) (B) Quantitative analysis of connexin-43 mRNA levels in whole cardiac left ventricle. (C) Representative immunoblots for eNOS protein
expression. Diagram bars show the results of densitometric analysis of eNOS in whole cardiac left ventricle. (D) Quantitative analysis of eNOS mRNA levels in whole
cardiac left ventricle Data are presented as means ± SEM of observations obtained for 5–8 tissue samples from 5 to 8 animals per treatment. A one-way ANOVA
followed by Bonferroni/Dunn post hoc test was used for statistical analysis (∗P < 0.05, CPT 2 mg/kg vs. control, ∗∗∗P < 0.001, CPT 2 mg/kg vs. control,
+++P < 0.001, CPT 3 mg/kg vs. control, $P < 0.05, CPT 3 mg/kg vs. CPT 2 mg/Kg, $$P < 0.01, CPT 3 mg/kg vs. CPT 2 mg/Kg).
that, at the highest dose of the antitumor drug used, a significant
decrease in the DBP and a slight, although not significant
bradycardia occur. SBP was not modified after treatments, and
HR was not altered after low and intermediate cisplatin doses
assayed. It was demonstrated that cisplatin chronic treatment
at similar doses (1–3 mg/kg) than those evaluated in the
present work caused peripheral sensory and enteric autonomic
neuropathy (Vera et al., 2011, 2013). Our results show that
cisplatin chronic treatment could also provoke an autonomic
cardiovascular neuropathy resulting in a decrease in DBP
and slight bradycardia, pointing out that this cardiovascular
autonomic neuropathy occurs at higher doses than the sensory
or enteric neuropathies that have been shown at treatment doses
of cisplatin of 1 and 2 mg/kg (Vera et al., 2011, 2013). Different
authors describe that cisplatin induced severe bradycardia in
humans (Darling, 2015; Schlumbrecht and Hehr, 2015; Kounis
et al., 2016), and other authors describe, after a single injection
of cisplatin (7 mg/kg) in rats, cardiac alterations that include
a decrease in blood pressure as well as a decrease in HR, due
to the cardiotoxicity that cisplatin produces in the sinoatrial
node, which leads to bradycardia (El-Sawalhi and Ahmed, 2014).
On the other hand, cisplatin causes nephrotoxicity primarily
causing tubulointerstitial lesions that provoke the urine waste
of electrolytes (Vickers et al., 2004; Yao et al., 2007). Besides, it
has also been demonstrated that most cisplatin-treated patients
waste sodium, potassium, magnesium, and calcium in their urine
and some have orthostatic hypotension (Lajer and Daugaard,
1999; Goren, 2003). In our study, renal toxicity has not been
evaluated, but it is possible that both phenomena, cardiac and
renal toxicities, were also related. In fact, understanding the
mechanisms of cisplatin-induced renal and cardiac toxicities
may help provide better treatment and preventive strategies
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FIGURE 7 | Representative immunoblots for plasminogen activator
inhibitor-1 (PAI-1) protein expression in whole cardiac left ventricle.
Diagram bars show the result of densitometric analysis of PAI-1 in whole
cardiac left ventricle. Data are presented as means ± SEM of observations
obtained of 6–8 tissue samples from 6 to 8 animals per treatment. A one-way
ANOVA followed by Bonferroni/Dunn post hoc test was used for statistical
analysis.
(Dugbartey et al., 2016). More research is needed to investigate
this aspect. It is important to note that the fact that neither
SBP nor HR were modified could suggest that we detected
cisplatin-induced cardiovascular neurotoxicity still at an initial
developmental stage.
In cancer patients treated with chemotherapy, there is greater
cardiovascular morbidity and mortality than in the general
population, especially and worryingly in patients younger than
45 (van den Belt-Dusebout et al., 2006). The most evaluated
cardiac toxicity is that produced by anthracyclines (Hirano et al.,
1993; Soga et al., 2006; Berdichevski et al., 2010; Shaker and
Sourour, 2010). However, this cardiotoxicity is not unique to
this group of antineoplastic drugs, but may occur with other
antitumoral agent groups (Al-Majed et al., 2006; Drimal et al.,
2006; Hernández-Esquivel et al., 2006; Sudharsan et al., 2006),
including cisplatin (Pai and Nahata, 2000). It was reported that
treatment with a single dose of cisplatin causes left ventricular
dysfunction and depression of cardiomyocyte contractility in the
rat. These alterations may be related to mitochondrial function,
oxidative stress and an increase in apoptosis (Ma et al., 2010; El-
Sawalhi and Ahmed, 2014). The results obtained in this study
confirm that chronic cisplatin produces a significant decrease in
cardiac contractility, associated with a decrease in dilatory left
ventricular function. Moreover, this left ventricular dysfunction
could be related to the decrease in DBP observed after cisplatin at
3 mg/kg/week. Other authors, using similar or even lower doses
but in an acute administration pattern, obtained similar results
(Ma et al., 2010; Ciftci et al., 2011; El-Awady et al., 2011; Hussein
et al., 2012; Coskun et al., 2014; El-Sawalhi and Ahmed, 2014).
In this study, it has been also evaluated the possible
mechanism involved in the left ventricular dysfunction observed
after cisplatin treatment. Connexins are structural proteins that
bind to form gap bonds in vertebrates, and connexin-43 is a
member of this family. Gap junctions allow the passage of small
ions and molecules, directly connecting the cytoplasm of adjacent
cells, and are of special importance in the heart, since they make
possible the coordinated depolarization of the cardiac muscle. An
increase in the expression of connexin-43 has been described in
cisplatin-resistant tumor cell lines, which seems to be linked to
the resistance of the cells to this drug (Li et al., 2006). However,
the expression of this protein in cardiac tissue of animals treated
with cisplatin has not been extensively studied. Our results show
that cardiac architecture was altered when increasing the dose
of cisplatin, with occurrence of rippled cardiomyocytes and
fibrils de-arrangement. Moreover, an increase in connexin-43
expression in hearts of cisplatin-treated animals was observed
with the dose of 2 mg/kg and higher. This data suggests that
cisplatin can produce direct cytotoxicity in cardiac cells and
that they can respond with an increase of connexin-43. Other
authors have also described the cytotoxicity of acute (10 mg/kg)
or chronic (4 mg/kg one a week for 4 weeks) administration
of cisplatin that resulted in structural alterations in cardiac
tissue in which separated cardiac muscles with interruption of
myofibrils and severe interstitial hemorrhages or fibrosis were
observed (Jiang et al., 2014; Saleh et al., 2015). It is important
to note that connexin-43 RNAm levels were not modified after
the antitumoral treatments. It is possible that alterations in some
transcription and post-transcriptional factors or inhibition of
connexin-43 degradation play a role in the regulation of connexin
expression (Salameh et al., 2004).
It is known that an elevated level of PAI-1 is also an important
profibrotic marker of cardiac fibrosis (Ghosh and Vaughan,
2012); and that an increased expression of myocardium PAI-1
contributes to ventricular remodeling and fibrosis that could be
related to ventricular dysfunction (Takeshita et al., 2004; Shimizu
et al., 2016). The result of the present study show that PAI-1
cardiac expression was not modified after the different cisplatin
treatments, what could suggest that cardiac alterations in our
experimental protocol were at an incipient stage. Other authors
have described an increase of PAI-1 in cardiomyocytes treated
with other chemotherapeutic agents as doxorubicin (Ghosh et al.,
2016).
On the other hand, heart eNOS was heterogeneously
distributed and eNOS expression and eNOS mRNA levels
were diminished after cisplatin treatment at the higher doses
assayed. Our data are in agreement with those showed by
Saleh et al. (2015) that also described a significantly decrease in
nitric oxide levels in heart homogenates after chronic cisplatin
treatments. However, after acute cisplatin administration, other
authors show a significant increase in the level of nitric oxide
in heart (Jiang et al., 2014). It is possible that the repeated
pattern of administration used in this study can ameliorate
this increase. Besides, it is known that overproduction of
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FIGURE 8 | Representative images of histology and immunohistochemistry of the effect of cisplatin treatment on rat aorta. Rats were injected
intraperitoneally for 5 weeks with saline (0.9% NaCl, left column) or cisplatin (3 mg/kg week−1, right column). Histological samples embedded in paraffin and stained
with Masson’s trichrome (A,B). Samples processed for immunohistochemistry with anti eNOS antibody (C,D). Bar: 100 µm.
nitric oxide was directly linked to heart damage in other
models of chemotherapeutic agents-induced cardiotoxicity, as in
cyclophosphamide (Mythili et al., 2004), and doxorubicin (Ghibu
et al., 2012). However, our data suggest that chronic cisplatin
treatment does not cause this increase. More research is needed
to evaluate more deeply this alteration.
Regarding functionality of blood vessels, the results obtained
showed that chronic cisplatin treatment provoked an altered
vascular relaxant but not vascular contractile function in aorta,
indicating the presence of a clear endothelial dysfunction in a
large artery. This endothelial dysfunction did not occur at the low
dose evaluated of the chemotherapeutic agent but was present at
2 and 3 mg/kg. It is important to note that the magnitude of this
endothelial dysfunction is not dose-dependent since the doses
of 2 and 3 mg/kg induced a similar decrease in the endothelial
function. Endothelial dysfunction in large arteries has been also
described in humans (Turlapaty and Altura, 1980; Rosenfeld and
Broder, 1984; Samuels et al., 1987; Serrano-Castro et al., 2000;
Pretnar-Oblak et al., 2007). On the other hand, endothelium-
independent vasorelaxation in aorta was augmented by the
maximum dose of cisplatin evaluated, which indicates a greater
facility of cisplatin to produce direct relaxation in vascular
smooth muscle at this dose. Recently, it has been described, in
rats, that cisplatin (200 µM) decreased contractile function in
thoracic aorta and that this effect was caused by a severe damage
to blood vessel walls (Jiang et al., 2014). This fact could explain the
potentiation of endothelial-independent vasorelaxation observed
in our study in aorta after the administration of 3 mg/kg of
cisplatin. However, this fact is in contrast with the endothelial
dysfunction observed. The resistance vascular territory was
differently affected by chronic cisplatin treatment. Thus, in the
mesenteric vascular bed, cisplatin treatment did not provoke
any modification in the vasorelaxant function at any of the
three different cisplatin doses evaluated, but caused a significant
reduction in the vasocontractile function of this vascular bed that
is compatible with the existence of an autonomic neuropathy
at this level. In fact, Authier and Coworkers pointed out that
peripheral nerve conduction velocities were decreased in cisplatin
(3 mg/kg) treated rats (Authier et al., 2003). Moreover, in
cisplatin-treated patients a similar decrease in nerve conduction
velocity occurred after cumulative doses of 200–400 mg/m2
(Boogerd et al., 1990). It is possible that cumulative cisplatin
doses of 10 or 15 mg/kg are not high enough to produce this
altered alpha-vasoconstrictor response in large vessels, whereas
resistance territories may be more sensitive to its neuronal
toxicity. In the literature, there is no experimental data about
cisplatin toxicity on resistance vascular vessels, to which we could
compare the result obtained in the present work. More research
is needed to completely establish the differences found between
resistance and large vascular territories in contractile function
after cisplatin treatments.
Regarding the endothelial dysfunction observed only in
large but not in resistance vessels, it is possible that vascular
endothelial dysfunction in large vessels occurs prior to vascular
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FIGURE 9 | (A) Representative immunoblots for eNOS protein expression in aorta. Diagram bars show the result of densitometric analysis of eNOS in aorta.
(B) Quantitative analysis of eNOS mRNA levels in aorta. (C) Representative immunoblots for plasminogen activator inhibitor-1 (PAI-1) protein expression in aorta.
Diagram bars show the result of densitometric analysis of PAI-1 in aorta. Data are presented as means ± SEM of observations obtained for 5–8 tissue samples from
5 to 8 animals per treatment. A one-way ANOVA followed by Bonferroni/Dunn post hoc test was used for statistical analysis.
autonomic neuropathy in cisplatin treatments. In addition,
endothelial dysfunction may be more sensitive and therefore
dysfunction may occur even at low doses. This pattern of events
is not surprising. In fact, other authors have shown in other
autonomic peripheral neuropathies, such as diabetic neuropathy,
that impairment of acetylcholine-mediated vascular relaxation
occurs prior to nerve blood flow and conduction deficits (Oltman
et al., 2005).
Finally, in order to identify the possible molecular mechanism
by which cisplatin caused the vascular toxicity described here,
histological, Western Blot and quantitative PCR analyses were
performed. Methodological problems have impeded us to carry
out these experiments in mesenteric vessels, but they have been
carried out in aorta. Structural alterations occurred in aorta after
chronic cisplatin treatment. The results obtained show changes
in fiber arrangement in the tunica media, losing their uneven
appearance. The fundamental structural and functional unit of
the aortic wall is the medial lamellar unit. The medial layer
comprises elastic membrane layers between which the smooth
muscle layer and a small amount of collagen and elastic fibers are
encountered. The integrity of the vascular smooth muscle layer is
crucial in the maintenance of normal vascular morphology and
tone. Changes in arterial wall composition and function underlie
all forms of vascular disease (Dabagh et al., 2008). Other authors
have also described, after acute administration of cisplatin at
5 mg/kg, severe damage to the smooth muscle layer of aorta
(Jiang et al., 2014). Furthermore, Saleh et al. (2015) also described
an increased thickening in tunicae intima and media with an
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irregular luminal layer of endothelial cell linings in aorta from
chronic cisplatin treated rats. In the present study, histological
analysis also showed that eNOS staining disappeared in the
animals treated chronically with cisplatin at 3 mg/kg. However,
it was surprising that eNOs expression or eNOs RNAm levels
were not altered in aorta after the different cisplatin treatments.
It is possible that endothelial dysfunction also was in an incipient
stage or that other mechanisms were involved in cytotoxic effect
of cisplatin in blood vessels. It is known that there is a relationship
between endothelial dysfunction and vascular PAI-1 upregulation
(Endemann and Schiffrin, 2004; Vaughan, 2005). So, in the
present work, the expression of PAI-1 was also evaluated in aorta.
Cisplatin treatments induced slightly but not significant increases
in PAI-1 expression in aorta tissue. More research is needed to
determine the possible role of other mechanisms involved in
cytotoxic effect of cisplatin in blood vessels.
CONCLUSION
In summary, the results of this study show that chronic
treatment with cisplatin induces cardiovascular alterations. These
cardiovascular alterations do not affect equally all cardiovascular
organs/tissues and they do not occur at the same doses
of the antitumor treatment. Thus, at low doses, chronic
treatment with cisplatin seems safe for the cardiovascular system,
since no alterations are observed. However, at intermediate
doses, alterations, such as endothelial dysfunction in vessels of
conductance, are apparent. At higher doses, this endothelial
dysfunction is maintained, and other alterations also develop.
In this sense, the autonomic neurotoxicity begins affecting
resistance vessels and cardiac function, and this finally causes
general symptoms such as hypotension. These functional
alterations at the cardiovascular level are accompanied by
structural alterations in cardiac and vascular tissue. Changes in
connexin-43 and eNOS expression could be related with cardiac
functional alterations after cisplatin treatments.
Both traditional and novel anticancer agents are used with
curative purpose. However, limiting cardiovascular problems
of these therapeutic drugs has become a priority. In this
sense, experimental studies directed to the identification and
understanding of the mechanisms involved in this particular
toxicity could be useful to the scientific community. In the
present study, the experimental conditions used provoked in
the animals, cardiovascular alterations similar to those described
in humans treated with cycles of cisplatin (Demkow and
Stelmaszczyk-Emmel, 2013; Haugnes et al., 2015; Herrmann
et al., 2016), being a useful tool for this purpose. However, further
investigations are needed to identify early signs of cardiac and
vascular damage in order to optimize the clinical management of
cardiotoxicity in cisplatin treatments.
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